Joyce A. O’Shaughnessy

home / authors / joyce-a-o-shaughnessy

Articles

TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

Aditya Bardia, MD, MPH;Virginia Kaklamani, MD, DSc;Joyce A. O’Shaughnessy;Peter Schmid, MD;J. Thaddeus Beck,;Michelino De Laurentiis;Guiseppe Curigliano;Hope S. Rugo, MD;Carlos Barcenas;William J. Gradishar, MD;Michail Ignatiadis;David Cameron;Giulia Tonini;Simona Scartoni;Jennifer Crozier;Leo Viana Nicacio;Tomer Wasserman;Sara M. Tolaney, MD, MPH
June 18th 2025
30 Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2– Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial

30 Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2– Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial

Aarti Chawla;Komal Jhaveri;Patrick Neven, MD, PhD;Monica Lis Casalnuovo;Sung-Bae Kim;Eriko Tokunaga;Philippe Aftimos;Cristina Saura;Joyce A. O’Shaughnessy;Nadia Harbeck, MD, PhD;Lisa A. Carey, MD;Guiseppe Curigliano;Antonio Llombart-Cussac;Elgene Lim, MBBS, FRACP, PhD;María de la Luz García Tinoco;Joohyuk Sohn;Andre Mattar;Qingyuan Zhang;Chiun-Sheng Huang;Chih-Chiang Hung;Jorge Luis Martinez Rodriguez;Manuel Ruiz Borrego
June 16th 2025
42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

Ana Sandoval;Joyce A. O’Shaughnessy;Astra M. Liepa;Brenda Grimes;Katheryn Moreira;James Roose;Catherine Keane;Sara M. Tolaney, MD, MPH
May 29th 2025
46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study

46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study

Heather McArthur, MD, MPH;Peter A. Fasching;Rebecca Dent, MD;Javier Cortés, MD;Lajos Pusztai, MD, DPhil;Sherko Kuemmel;Carsten Denkert;Yeon Hee Park;Rina Hui;Nadia Harbeck, MD, PhD;Masato Takahashi;Seock-Ah Im;Michael Untch, MD, PhD;Marie-Ange Mouret-Reynier;Theodoros Foukakis;Marta Ferreira;Fatima Cardoso;Yu Ding;Cecilia Pinheiro;Jaime Mejia;Joyce A. O’Shaughnessy;Peter Schmid, MD
May 26th 2025
TPS 105 ALISertib in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Recurrent or Metastatic Breast Cancer: the Phase 2 ALISCA-Breast1 Study

TPS 105 ALISertib in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Recurrent or Metastatic Breast Cancer: the Phase 2 ALISCA-Breast1 Study

Pooja Advani, MBBS, MD;Sofia Braga;Adam M. Brufsky, MD, PhD;Karthik V. Giridhar;Erica L. Mayer, MD, MPH;Kelly E. McCann;Ruth M. O’Regan;Cristina Saura;Seth A. Wander;Georg F. Bischof;Beth H. Lowenthal;Judith D. Bebchuk;Lisa D. Eli;Brian G. Barnett;Joyce A. O’Shaughnessy;Tufia C. Haddad
April 11th 2025
29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)

29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Erika P. Hamilton, MD;Sara A. Hurvitz, MD;Sara M. Tolaney, MD, MPH;Virginia Kaklamani, MD, DSc;Paula Muñoz Romero;Shannon Matheny;Kathy Puyana Theall;Joyce A. O’Shaughnessy
July 21st 2024
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer

36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer

Matthew P. Goetz, MD;Masakazu Toi;Jens Huober, MD;Joohyuk Sohn;Oliver Trédan;In Hae Park;Mario Campone;Shin-Cheh Chen;Luis Manuel Manso;Shani Paluch-Shimon;Orit C. Freedman;Joyce A. O’Shaughnessy;Xavier Pivot;Sara M. Tolaney, MD, MPH;Sara A. Hurvitz, MD;Antonio Llombart;Valérie André;Abhijoy Saha;Gertjan van Hal;Ashwin Shahir;Hiroji Iwata;Stephen R.D. Johnston
June 23rd 2024
17 A Clinical Systematic Literature Review of Treatments Among Patients With Advanced/ Metastatic HER2+ Breast Cancer

17 A Clinical Systematic Literature Review of Treatments Among Patients With Advanced/ Metastatic HER2+ Breast Cancer

Kerigo Ndirangu;Rachel Goldgrub;Vanita Tongbram;Rajee Antony;Bagrat Lalayan;Joyce A. O’Shaughnessy;Sarah E. Schellhorn
April 28th 2023
50 Pooled Exploratory Analysis of Survival in Patients (pts) With HR+/ HER2− Advanced Breast Cancer (ABC) and Visceral Metastases (mets) Treated With Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) Trials

50 Pooled Exploratory Analysis of Survival in Patients (pts) With HR+/ HER2− Advanced Breast Cancer (ABC) and Visceral Metastases (mets) Treated With Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) Trials

Denise A. Yardley, MD;Yoon Sim Yap;Hamdy Abdel Azim;Richard De Boer;Mario Campone;Alistair Ring;Michelino De Laurentiis;Joyce A. O’Shaughnessy;Javier Cortes;Yogesh Chattar;Astrid Thuerigen;Juan Pablo Zarate;Liz Santarsiero
April 27th 2023
55 TIP ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Women and Men With Metastatic Breast Cancer (mBC)

55 TIP ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Women and Men With Metastatic Breast Cancer (mBC)

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Javier Cortes;Giuseppe Curigliano;Erika P. Hamilton, MD;Sara A. Hurvitz, MD;Sibylle Loibl;Simona Scartoni;Tarek Sahmoud, MD;Krzysztof J. Grzegorzewski;Nassir Habboubi;Joyce A. O’Shaughnessy
April 27th 2023
Early-Stage Monitoring and Adverse Event Mitigation for Patients with HER2-Postitive Breast Cancer

Early-Stage Monitoring and Adverse Event Mitigation for Patients with HER2-Postitive Breast Cancer

Joyce A. O’Shaughnessy
October 27th 2022

Dr. Joyce O’Shaughnessy closes the discussion with considerations for clinicians on monitoring patients with HER2-psotive breast cancer.

Discussing Treatment and Management Strategies with Patients in the HER2-Positive Setting

Discussing Treatment and Management Strategies with Patients in the HER2-Positive Setting

Joyce A. O’Shaughnessy
October 20th 2022

Advice for clinicians on how to discuss treatment and management strategies with patients with HER2-postitive breast cancer.

The Impact of COVID-19 on Treatment Decisions Across Patients with HER2-Positive Breast Cancer

The Impact of COVID-19 on Treatment Decisions Across Patients with HER2-Positive Breast Cancer

Joyce A. O’Shaughnessy
October 20th 2022

Discussion centered around the how the COVID-19 pandemic has influenced clinical treatment decisions across patients with HER2-positive breast cancer.

Data Review and Key Insights: The FeDeriCa Trial and PHranceSCa Study

Data Review and Key Insights: The FeDeriCa Trial and PHranceSCa Study

Joyce A. O’Shaughnessy
October 13th 2022

Dr. Joyce O’Shaughnessy briefly reviews and provides insights into the FeDeriCa and the PHranceSCa studies.

Pertuzumab and Trastuzumab: Patient Eligibility, Administration Methods, and Dosing Strategies

Pertuzumab and Trastuzumab: Patient Eligibility, Administration Methods, and Dosing Strategies

Joyce A. O’Shaughnessy
October 13th 2022

Clinical insights concerning the administration of combination pertuzumab/trastuzumab/hyaluronidase-zzxf for patients with HER2-positive breast cancer.

A Generalized Approach to First-Line HER2-Positive Breast Cancer Treatment

A Generalized Approach to First-Line HER2-Positive Breast Cancer Treatment

Joyce A. O’Shaughnessy
October 7th 2022

A breast cancer expert shares the current first-line standard of care for patients with HER2-positive breast cancer and presents scenarios where the standard treatment approach may not be appropriate.

The HER2-Positive Breast Cancer Landscape

The HER2-Positive Breast Cancer Landscape

Joyce A. O’Shaughnessy
October 7th 2022

Joyce O’Shaughnessy, MD shares an overview of the HER2-positive breast cancer landscape, focusing on prognosis and risk of recurrence for patients with early-stage and metastatic breast cancer.

7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 Inhibitor

7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 Inhibitor

Adam M. Brufsky, MD, PhD;Hannah M. Linden, MD;Hope S. Rugo, MD;Joyce A. O’Shaughnessy;Robert H. Getzenberg;K. Gary Barnette;Domingo Rodriguez;Mitchell Steiner;Erica L. Mayer, MD, MPH
April 18th 2022
8 TiP Randomized, Multicenter, Phase 3 Study to Evaluate the Combination of Enobosarm and Abemaciclib Compared With Estrogen-Blocking Agent for the Second-Line Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Have Previously Received Palbociclib and an Estrogen-Blocking Agent Combination Therapy

8 TiP Randomized, Multicenter, Phase 3 Study to Evaluate the Combination of Enobosarm and Abemaciclib Compared With Estrogen-Blocking Agent for the Second-Line Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Have Previously Received Palbociclib and an Estrogen-Blocking Agent Combination Therapy

Elgene Lim, MBBS, FRACP, PhD;Adam M. Brufsky, MD, PhD;Hope S. Rugo, MD;Charles L. Vogel, MD, FACP;Joyce A. O’Shaughnessy;Robert H. Getzenberg;K. Gary Barnette;Domingo Rodriguez;Mitchell Steiner;Hannah M. Linden, MD
April 18th 2022

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Expanding Immunotherapy Use in Early-Stage Breast Cancer
Published: July 14th 2025 | Updated: July 25th 2025
Expanding Immunotherapy Use in Early-Stage Breast Cancer